Lyme Test Indication Combinations (LyTIC) Study (LyTIC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03201042 |
|
Recruitment Status :
Terminated
(Sponsor Decision)
First Posted : June 28, 2017
Last Update Posted : December 13, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Lyme Disease | Diagnostic Test: PCR based assay Diagnostic Test: Serology based assay Diagnostic Test: Tcell based assay |
| Study Type : | Observational |
| Actual Enrollment : | 410 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Lyme Test Indication Combinations (LyTIC) Study |
| Actual Study Start Date : | June 8, 2017 |
| Actual Primary Completion Date : | November 30, 2018 |
| Actual Study Completion Date : | November 30, 2018 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
1a:Lyme patients- Erythema Migrans(EM)rash present
Patients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
|
Diagnostic Test: PCR based assay
Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined. In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen). Diagnostic Test: Serology based assay
Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared. Diagnostic Test: Tcell based assay A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis. |
|
1b:Lyme patients no typical EM
Patients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
|
Diagnostic Test: PCR based assay
Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined. In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen). Diagnostic Test: Serology based assay
Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared. Diagnostic Test: Tcell based assay A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis. |
|
Cohort 2: healthy controls
Patients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
|
Diagnostic Test: PCR based assay
Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined. In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen). Diagnostic Test: Serology based assay
Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared. Diagnostic Test: Tcell based assay A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis. |
- Sample Data Analysis [ Time Frame: Tests at different time points post inital presentation will be evaluated through study completion, an average of 1 year. ]The results will be used to calculate performance, including sensitivity and specificity of the tests under evaluation. The utility of these tests at different time points post initial presentation will be evaluated.
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 5 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- Cohort 1a (typical EM and intention to treat):
Inclusion
- Documented new onset Lyme disease EM rash (single or multiple) with photographic evidence provided to Oxford Immunotec.
- Patient must be able to provide blood sample at the initial visit (prior to treatment initiation) and subsequent samples according to the schedule.
- Patients 5 years of age or older, with a minimum weight of 40 pounds.
- Patient able to read English and to give consent to study participation.
- If patient is younger than 18 years of age a legally authorized representative must provide consent.
Cohort 1b (no typical EM; Lyme disease symptoms; intention to treat):
Inclusion
- Patients with suspected Lyme disease, based on physician's examination, where the physician has the intention to treat for Lyme disease (i.e. patients who following initial examination were prescribed treatment for Lyme disease).
- Documented new onset of Lyme disease symptoms without a typical EM rash or with no rash. If a rash is present, photographic evidence must be provided.
- Patient must be able to provide blood sample at the initial visit (prior to treatment initiation) and subsequent samples according to the schedule.
- Patients 5 years of age or older, with a minimum weight of 40 pounds.
- Patient able to read English and to give consent to study participation.
- If patient is younger than 18 years of age a legally authorized representative must provide consent.
Cohort 2 (Healthy subjects):
Inclusion
- Subjects 5 years of age or older, with a minimum weight of 40 pounds.
- Subjects never diagnosed with any tick borne disease including Lyme disease
- Subjects able to read English and to give consent to study participation.
- If subject is younger than 18 years of age a legally authorized representative must provide consent.
Exclusion Criteria:
-
Exclusion Cohort 1a (typical EM and intention to treat):
- Patients with Lyme-like symptoms lasting longer than 1 month prior to study enrolment.
- Patients receiving treatment for any tick borne disease (including Lyme disease) prior to enrolment.
- Patients who received a Lyme vaccination.
- Patients with anemia defined as a serum hemoglobin <10gm/dL.
- Patients who are participating in, or plan to participate in, any investigational drug study.
- Patients who are considered unsuitable for the study by the Investigator.
Cohort 1b (no typical EM; Lyme disease symptoms; intention to treat):
- Patients with Lyme-like symptoms lasting longer than 1 month prior to study enrolment.
- Patients receiving treatment for any tick borne disease (including Lyme disease) prior to enrolment.
- Patients who received a Lyme vaccination.
- Patients with anemia defined as a serum hemoglobin <10gm/dL.
- Patients who are participating in, or plan to participate in, any investigational drug study.
- Patients who are considered unsuitable for the study by the Investigator.
Cohort 2 (Healthy subjects):
Exclusion
- Subjects with a history of tick bite
- Subjects with past or current tick borne disease diagnosis
- Subjects at risk for tick borne diseases including Lyme disease
- Subjects residing in endemic regions for tick borne diseases: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia and Wisconsin.
- Subjects who have ever visited non-urban areas of endemic regions for tick borne diseases: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia and Wisconsin.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03201042
Show 60 study locations
| Responsible Party: | Oxford Immunotec |
| ClinicalTrials.gov Identifier: | NCT03201042 |
| Other Study ID Numbers: |
L3 |
| First Posted: | June 28, 2017 Key Record Dates |
| Last Update Posted: | December 13, 2018 |
| Last Verified: | June 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Product Manufactured in and Exported from the U.S.: | No |
|
Lyme Disease Gram-Negative Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Infections |
Borrelia Infections Spirochaetales Infections Tick-Borne Diseases Vector Borne Diseases |